Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-09-06
2005-09-06
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S130100, C435S006120
Reexamination Certificate
active
06939547
ABSTRACT:
A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
REFERENCES:
patent: 5801042 (1998-09-01), Chang et al.
patent: 5849564 (1998-12-01), Chang et al.
patent: 5854398 (1998-12-01), Chang et al.
patent: 5861500 (1999-01-01), Chang et al.
patent: 5948676 (1999-09-01), Chang et al.
patent: WO 98/03657 (1998-01-01), None
patent: WO 98/04576 (1998-02-01), None
Aoki et al.,Blood93(12):4034-4043 (1999).
Aoki et al.,Blood94(10):431a(1999) (Abstract only).
Aoki et al.,Blood96(11):572a (2000)(Abstract only).
Aoki et al.,Blood97(7):2173-2176 (2001).
Aoki et al.,Blood97(8):2526-2527 (2001).
Asou et al.,Blood91(7):2475-2481 (1998).
Brakenhoff et al.,Journal of Biological Chemistry369(1):86-93 (1994).
Burger et al.,Blood91(6):1858-1863 (1998).
Chow et al.,Science291:2150-2155 (2001).
Drexler et al.,Leukemia13(4):634-640 (1999) (Abstract only).
Hideshima et al.,Clinical Cancer Research6:1180-1189 (2000).
Hoischen et al.,Eur. J. Biochem.267:3604-3612 (2000).
Jones et al.,Blood94(8):2871-2879 (1999).
Molden et al.,Journal of Biological Chemistry272(31) 19625-19631 (1997).
Moore et al.,Science274(5293):1739, pp. 1-6 (2000).
Aoki Yoshiyasu
Tosato Giovanna
Klarquist & Sparkman, LLP
Salimi Ali R.
The United States of America as represented by the Department of
LandOfFree
Specific binding agents for KSHV vIL-6 that neutralize a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific binding agents for KSHV vIL-6 that neutralize a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific binding agents for KSHV vIL-6 that neutralize a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3389002